S35-Labeled Bendroflumethiazide in Human Beings
- 1 March 1964
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 113 (3) , 373-377
- https://doi.org/10.1001/archinte.1964.00280090059010
Abstract
Bendroflumethiazide (Naturetin)-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide —is a nonmercurial diuretic agent of the benzothiadiazine group, which is effective clinically in the treatment of edema and hypertension.1-5 We have previously studied 6,7 the renal excretion of chlorothiazide and hydrochlorothiazide labeled with radioactive carbon (C14) in normal subjects and in patients with various medical diseases associated with the retention of water and electrolytes. The cumulative renal excretion of radioactivity was lower in patients with cardiac, renal, and hepatic diseases than in normal subjects. The amount of radioactivity recovered in the urine appeared to be inversely proportional to the severity of the disease. In the present study, S35-labeled bendroflumethiazide was administered orally or intravenously to normal subjects and patients with cardiac, renal, and hepatic diseases. The cumulative renal excretion of radioactivity was compared with that of chlorothiazide and hydrochlorothiazide. Material and Methods Material. —A total of 23 studies were performed inThis publication has 1 reference indexed in Scilit:
- C14-Labeled Hydrochlorothiazide in Human BeingsArchives of internal medicine (1960), 1961